Yao Dong

Yao Dong


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2024 in Knowledge-Based Systems
Verified
Journal Article
Closed access
YDYao Dong
Yao Dong
YLYuxi Liu
Yuxi Liu
YDYongfeng Dong
Yongfeng Dong
YWYacong Wang
Yacong Wang
MCMin Chen
Min Chen

1 February 2022 in Neurocomputing
Verified
Journal Article
Closed access
YDYongfeng Dong
Yongfeng Dong
HXHuaxin Xiao
Huaxin Xiao
YDYao Dong
Yao Dong

5 July 2019 in Multimedia Tools and Applications
Verified
Journal Article
Closed access
PDF file
WLWei LI
Wei LI
JGJunhua Gu
Junhua Gu
YDYongfeng Dong
Yongfeng Dong
YDYao Dong
Yao Dong
JHJungong Han
Jungong Han

2 July 2025 in Briefings in Bioinformatics
Verified
Journal Article
Open access
YDYao Dong
Yao Dong
JZJiaxue Zhang
Jiaxue Zhang
JSJin Shi
Jin Shi
YHYushan Hu
Yushan Hu
XCXiaowen Cao
Xiaowen Cao
Xuekui ZhangXuekui Zhang
Xuekui Zhang
Single-cell multi-omics clustering confronts noise and heterogeneity barriers. Current multi-view anchor graph approaches, though successful in noise reduction, inadequately model higher order feature interactions. To address this issue, we propose scAGCI, a cell clustering method based on anchor graphs that integrates both scRNA-seq and scATAC-seq data. Our method captures specific and shared anchor graphs representing the properties of omics data in the process of dynamic anchor unification, and mines high-order shared information to complete the omics representation. Subsequently, clustering results are obtained by integrating the specific and shared omics representation. Benchmarking against 13 state-of-the-art methods confirms scAGCI’s superior clustering performance and computational efficiency in cell-type identification and subtype resolution. The method preserves biologically meaningful omics patterns, as evidenced by marker gene enrichment and functional analyses, establishing it as a robust tool for elucidating cellular heterogeneity in single-cell multi-omics data.

5 June 2024 in Artificial Intelligence and Law
Verified
Journal Article
Closed access
PDF file
YDYao Dong
Yao Dong
XLXinran Li
Xinran Li
JSJin Shi
Jin Shi
YDYongfeng Dong
Yongfeng Dong
CCChen Chen
Chen Chen

12 December 2025 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
YDYao Dong
Yao Dong
CCChen Chen
Chen Chen
JSJin Shi
Jin Shi
YHYushan Hu
Yushan Hu
XCXiaowen Cao
Xiaowen Cao
Xuekui ZhangXuekui Zhang
Xuekui Zhang
Cell clustering is crucial in single-cell multi omics research for identifying distinct cellular populations. Although there has been progress in integrating multi omics data for clustering, combining more than two types of omics data remains challenging due to the diversity and heterogeneity of these datasets. Traditional approaches typically use heterogeneous graphs that integrate only two types of omics data, constructing graphs with genes and cells as nodes and a single type of edge representing their relationships. However, this method has limitations as it overlooks cell-cell interactions and struggles to capture complex cellular dynamics. Additionally, the graph structure must be redesigned whenever new omics data are introduced, limiting the scalability of these models. To address these issues, we introduce MOH, a novel single cell clustering algorithm based on a multilayer multi-omics heterogeneous graph. MOH integrates three key single cell omics types: scRNA-seq, scATAC-seq, and spatial transcriptomics. It constructs a multilayer heterogeneous graph to simultaneously extract and enhance representations from all three omics layers, incorporating both intra layer and inter-layer edges to capture association and similarity relationships. This enriched representation leads to an accurate clustering results. Extensive experiments show that MOH outperforms six state-of-the-art methods on unsupervised clustering metrics, offering a precise and comprehensive analysis with consistent improvements across all evaluation criteria. Moreover, downstream analyses validate the results, revealing novel biological insights into immune disorder complications in cancer, cancer drug repurposing, and new signaling pathways, which merit fur their investigation and validation.